


SOCIO-ECONOMIC SITUATION IN THE FIRST 6 MONTHS OF 2022 AND FORECAST

In the first 6 months of 2022, Vietnam's economy has recovered with positive and breakthrough signals. According to the General Statistics Office, GDP in the second quarter was estimated to increase by 7.72% over the same period, the highest figure since 2011. GDP in the first half of 2022 rose by 6.42%, which is 5.74% higher than the same period in 2021 and 2.04% over the same period in 2020, however, still lower than the growth rate of 7.28% and 6.98 % of the same period in 2018 and 2019. Overall, the industry and construction sector continued to play the leading role in contributing to the GDP growth of the whole country (increased 7.70%, contributing 48.33%), followed by the impressive growth of the service sector (increased 6.60%, making up 46.60%) and the agriculture, forestry and fishery sector (grew 2.78%, accounting for 5.07%). Generally, in the first 6 months of 2022, the total import-export turnover of goods was estimated at USD 371.17 billion, rose 16.4% year over year, of which export turnover increased by 17.3%; import turnover went up by 15.5%. The balance of trade in goods in the first 6 months of 2022 was experiencing a trade surplus of 710 million USD. Prices of essential commodities on the world market increased sharply due to the negative impact of the battle between Russia and Ukraine and the disruption of the global supply chain after 2 years of the pandemic. Prices of crude oil, natural gas and liquefied natural gas rose most significantly since 2011, posing a risk of food and energy security crisis and putting great pressure on global inflation. In the face of uncertainties in the world economy, ADB in its "Asian Development Outlook" report released in July, lowered its growth forecast for Asia to 4.6% from 5.2% announced in April, but maintained its forecast for Vietnam's economic growth at 6.5% in 2022 and 6.7% in 2023. Vietnam's economy grew due to easing measures, created momentum for the rapid recovery of travel activities and production expansion. In addition, the stimulation of public investment disbursement is also one of the factors that boost the economy grow.



Source: General Statistics Office of Vietnam

VIETNAM PHARMACEUTICAL INDUSTRY IN THE FIRST 6 MONTHS OF 2022 AND FORECAST

Vietnam's healthcare sector has also made great efforts in the first 6 months of 2022, plans and targets are on right track. However, it is still facing many challenges due to the emergence of new strains of Omicron variants named BA.4, BA.5 of the Covid-19 pandemic, the dengue epidemic in Southern Vietnam is also complicated. Encountering opportunities and challenges, pharmaceutical enterprises persevere in the struggles. Analytical results from the General Statistics Office showed that the production of drug manufacturing, pharmaceutical chemicals and herbals increased by 17.5% over the same period. Revenue was driven by the high growth of the pharmacy channel and the recovery of the hospital channel compared to the time of the pandemic. With ETC channel, due to the coverage of vaccines in the community, immunity is increasing, significantly reducing the number of people suffering from severe illness and death from Covid and lowering pressure on the health care system. Hospital capacity is saved more to treat other diseases. In addition, the demand for post-Covid healthcare at hospitals has also risen, creating a boost for ethical drug, but the ETC channel has not yet fully recovered as it was before the pandemic. The OTC channel maintains its growth rate due to the commercialization of Covid-19 medicine and people's need for home healthcare. It is forecasted that the scale of Vietnam's pharmaceutical industry would reach approximately VND 141,400 billion, increased 9.2% over the same period (Source: Vietnam News Agency), thanks to continued growth in demand for products to support resistance and disease prevention, along with the need for treatment of neurotropic, cardiovascular, respiratory, endocrine disorders, due to the long-term sequelae of COVID-19. It is expected that pharmaceutical sales in the hospital channel would have a strong bounce back, especially in the southern provinces, which helps the industry's revenue growth reach about 13% y/y in the second half of 2022 and 11% y/y for the whole of 2022 and recover nearly to pre-COVID-19 revenue levels.

Index of industrial production of June and 6 months 2022				
	May2022/May2021	June2022/May2022	June2022/June2021	6months2022/6months2021
Manufacturing	111.0	100.6	113.1	109.7
Manufacture of paper and paper products	96.9	101.9	114.1	108.2
Printing and reproduction of recorded media	101.6	114.5	104.3	108.0
Manufacture of coke and refined petroleum products	101.3	104.7	105.5	98.6
Manufacture of chemicals and chemical products	99.5	103.5	103.7	103.5
Manufacture of pharmaceuticals, medicinal chemical and botanical products	138.6	100.7	120.4	117.5


Source: General Statistics Office of Vietnam



IMEXPHARM STOCK MOVEMENT Q2 2022

The total trading volume of IMP shares in the second quarter of 2022 reached 324,300 shares, decreased 60% compared to the first quarter of 2022 and was only about 8.7% of the ordering matching volume of the second quarter of 2021. The highest closing price in the second quarter of 2022 for IMP shares was VND 74,890/share (recorded on April 6, 2022), while the lowest price was VND 58,800/share (June 27, 2022). On average, every business day in the Q2 of 2022, there were 5,231 shares traded.

The closing price of the last trading session in June 2022 was VND 59,500, decreased by VND 13,826 /share in comparison with the closing price of the last round of March 2022. In addition, in the Q2, the shareholder-SK Investment Vina III still held the highest share ownership rate in Imexpharm (46.57%).



IMEXPHARM ACTIVITIES IN THE FIRST 6 MONTHS OF 2022

BUSINESS RESULTS

Imexpharm's total revenue and income in the first 6 months of 2022 reached VND 682.8 billion, increased 9.5% over the same period and made up to 47.1% of the annual plan set by the General Meeting of Shareholders. Imexpharm's OTC channel grew nearly 47% and accounted for 64.5% of the revenue structure. Meanwhile, ETC channel witnessed negative growth of 13.6% in the first 6 months of 2022 due to the influence of the general context of the Vietnamese market. Imexpharm products still play the leading role in the revenue structure with 97.6%.

In the first half of 2022, Imexpharm recorded a growth of 7.1% in pre-tax profit compared to the first half of 2021 and reached 45.5% of the year plan. Cost of goods sold increased by nearly 9.0% to VND 385 billion. Selling and administrative expenses both increased by 5.3% and 31.1%, respectively, to VND 114.9 billion and VND 43.9 billion induced by higher fuel prices.

TOTAL ASSETS - EQUITY

As of June 30th, total assets were VND 2,097.2 billion, decreased 8.6% compared to the beginning of the year, mainly from debt reduction. IMP's equity increased by 4.3% in comparison with the end of the second quarter of 2021 and decreased slightly compared to the beginning of 2022, because IMP has paid cash dividends to shareholders in the 2nd quarter. IMP's charter capital has not changed compared to June 30th, 2021.

PAYABILITY - PROFITABILITY

Current ratio increased 0.3 times while quick ratio rose slightly over the same period. In general, the liquidity ratios are kept within a safe range and consistent with IMP's conservative working capital management strategy.

ROE, ROA in the last 4 quarters also decreased compared to the previous period because the profit after tax of the third quarter and the fourth quarter of 2021 plummeted compared to the same period because of the pandemic outbreak in Ho Chi Minh City and the southern provinces, and concurrently average equity and average total assets increased slightly over the same period. Besides, 4-quarter EPS also decreased by 5.4% y/y due to the impact of lower profits in the second half of 2021. ROS also dropped slightly.

IMP's stock price closed on June 30, 2022 at VND 59,500, down 25% compared to the closing price of the last session in Q2 2021. Because the closing price at the end of the second quarter of 2022 declined dramatically compared to the same period last year, so P/E and P/B decreased by 6.1 and 0.8 times respectively.

KEY ACTIVITIES OF Q2 AND PLAN FOR Q3 2022

On April 25th, 2022, Imexpharm successfully held the 2022 General Meeting of Shareholders and implemented the Resolution of the General Meeting of Shareholders. During the period, IMP completed the distribution of profits as well as paying the 2021 cash dividend to Shareholders. In addition, IMP also regularly organized sales promotion activities to gradually resume business activities after the pandemic.

As planned for the third quarter of 2022, Imexpharm will continue to promote sales activities, while controlling costs and monitoring exchange rate fluctuations to have a reasonable inventory policy. Departments continue to strengthen debt management and tightly control costs to achieve business goals in 2022.

No.	Financial ratios	6 ^m 2022	%Planned 2022	6 ^m 2021	Growth
I Operational results (VND billion)					
1	Total net revenue and other incomes	682.8	47.1%	623.8	9.5%
2	Net Revenue	668.7		613.9	8.9%
3	Cost of goods sold	385.0		353.2	9.0%
4	Selling expenses	114.9		109.1	5.3%
5	Administrative expenses	43.9		33.5	31.0%
6	Operating profit	124.8		112.7	10.7%
7	Profit before tax	125.2	45.5%	116.9	7.1%
8	Profit after tax	99.2		91.2	8.8%
II Assets - Resources (VND billion)					
1	Total assets	2,097.2		2,228.8	-6.7%
2	Owner's Equity	1,770.1		1,696.5	4.3%
3	Charter capital	667.1		667.1	0.0%
III Ability to pay (times)					
1	Current ratio	2.9		2.6	0.3
2	Quick ratio	1.6		1.5	0.1
IV Profitability					
1	Profit before tax / Net Revenue	18.7%		19.0%	-0.3%
2	ROS	14.8%		14.9%	-0.1%
3	ROE (The last 4 quarters)	11.4%		13.0%	-1.6%
4	ROA (The last 4 quarters)	9.1%		10.2%	-1.1%
5	EPS (basic) The last 4 quarters (VND)	2,643		2,793	-5.4%
6	BV (VND)	26,550		25,446	4.3%
7	P/E (times)	22.5		28.6	-6.1
8	P/B (times)	2.2		3.0	-0.8
Closing price on 30 th June (VND)		59,500.0		79,800.0	-25.4%